PD-L1 expression in different sample categories
| TPS | Diagnosis, n (%) | Sample site, n (%) | Sample type, n (%) | Sample preparation, n (%) | ||||||||
| ADC | SQCC | NOS | Other | Lung | Metastasis | FNA | Surgical resection | Biopsy | CB | Paraffin blocks | Unstained section | |
| <1% | 62 (63.9) | 23 (65.7) | 14 (56) | 22 (61.1) | 53 (60.2) | 35 (70) | 33 (80.5) |
31 (60.8) P= 0 . 0412 |
56 (55.4) P= 0 . 0052 | 33 (80.5) |
69 (57.5) P=0.0084 |
18 (56.3) P=0.0251 |
| 1%–49% | 16 (16.5) | 8 (22.9) | 4 (16) | 6 (16.7) | 17 (19.3) | 7 (14) | 6 (14.6) | 12 (23.5) | 16 (15.8) | 6 (14.6) | 22 (18.3) | 6 (18.8) |
| >50% | 19 (19.6) | 4 (11.4) | 7 (28) | 8 (22.2) | 18 (20.5) | 8 (16) | 2 (4.9) | 8 (15.7) |
29 (28.7) P=0.0018 | 2 (4.9) |
29 (24.2) P=0.0068 |
8 (25) P=0.0131 |
| Total | 97 | 35 | 25 | 36 | 88 | 50 | 41 | 51 | 101 | 41 | 120 | 32 |
Values in bold indicate statistically significant difference in sample type and sample preparation categories between surgical resection/biopsy versus FNA and paraffin blocks/unstained section versus CB, at cut-off TPS<1% and >50%.
SQCC squamous cell carcinoma; ADC, adenocarcinoma;CB, cell block; FNA, fine needle aspiration; NOS, not otherwise specified; PD-L1, programmed death ligand-1; TPS, tumour proportion score.